Given the previously discussed shortcomings of native phosvitin and the greater likelihood of enhanced intestinal uptake of shorter peptides, PPP appears to be a viable target for future studies into bone health and the management of osteoporosis. The gene discussed is CSNK2B; the disease is osteoporosis.